Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Luetkemeyer

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Seminars in Neurology|April 10, 2014
HIV-associated central nervous system tuberculosisGabriel Chamie, Carina Marquez, Anne Luetkemeyer
Open Forum Infectious Diseases|September 30, 2017
Disabling Dactylitis and Tenosynovitis Due to <i>Mycobacterium haemophilum</i> in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency SyndromeMichael H Woodworth, Carina Marquez, Henry Chambers, et al.
Sexually Transmitted Diseases|August 16, 2024
STD 50-Year Anniversary Issue Reflections on Navigating the Winding Road From Efficacy to Implementation for HIV Preexposure (PrEP) and Doxycycline PEP (Doxy-PEP)Connie Celum, Stephanie E Cohen, Julia C Dombrowski, et al.
Women'S Health Issues : Official Publication of the Jacobs Institute of Women'S Health|January 22, 2005
Willing and able? Provision of medication for abortion by future internistsEleanor Bimla Schwarz, Anne Luetkemeyer, Diana Greene Foster, et al.
Plos One|July 2, 2016
Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-CellsKapil K Saharia, Constantinos Petrovas, Sara Ferrando-Martinez, et al.
Research Square|May 3, 2024
Doxycycline post-exposure prophylaxis for sexually transmitted infections impacts the gut antimicrobial resistomeCharles Langelier, Victoria Chu, Abigail Glascock, et al.
HIV Clinical Trials|December 17, 2013
Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trialValerianna K Amorosa, Anne Luetkemeyer, Minhee Kang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 StudyDavid Wyles, Norbert Bräu, Shyam Kottilil, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 13, 2026
Performance Evaluation of the Xpert® HCV test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United StatesJennifer R Havens, Shelly-Ann Fluker, Jonathan Schimmel, et al.
The Lancet. Infectious Diseases|July 17, 2025
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled studyOnyema Ogbuagu, Jason D Goldman, Robert L Gottlieb, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Seminars in Neurology|April 10, 2014
HIV-associated central nervous system tuberculosisGabriel Chamie, Carina Marquez, Anne Luetkemeyer
Open Forum Infectious Diseases|September 30, 2017
Disabling Dactylitis and Tenosynovitis Due to <i>Mycobacterium haemophilum</i> in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency SyndromeMichael H Woodworth, Carina Marquez, Henry Chambers, et al.
Sexually Transmitted Diseases|August 16, 2024
STD 50-Year Anniversary Issue Reflections on Navigating the Winding Road From Efficacy to Implementation for HIV Preexposure (PrEP) and Doxycycline PEP (Doxy-PEP)Connie Celum, Stephanie E Cohen, Julia C Dombrowski, et al.
Women'S Health Issues : Official Publication of the Jacobs Institute of Women'S Health|January 22, 2005
Willing and able? Provision of medication for abortion by future internistsEleanor Bimla Schwarz, Anne Luetkemeyer, Diana Greene Foster, et al.
Plos One|July 2, 2016
Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-CellsKapil K Saharia, Constantinos Petrovas, Sara Ferrando-Martinez, et al.
Research Square|May 3, 2024
Doxycycline post-exposure prophylaxis for sexually transmitted infections impacts the gut antimicrobial resistomeCharles Langelier, Victoria Chu, Abigail Glascock, et al.
HIV Clinical Trials|December 17, 2013
Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trialValerianna K Amorosa, Anne Luetkemeyer, Minhee Kang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 StudyDavid Wyles, Norbert Bräu, Shyam Kottilil, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 13, 2026
Performance Evaluation of the Xpert® HCV test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United StatesJennifer R Havens, Shelly-Ann Fluker, Jonathan Schimmel, et al.
The Lancet. Infectious Diseases|July 17, 2025
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled studyOnyema Ogbuagu, Jason D Goldman, Robert L Gottlieb, et al.
Pageof 2